

Elisa Giovannetti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6015903/elisa-giovannetti-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

302
papers

12,654
citations

50
h-index

104
g-index

361
ext. papers

15,069
ext. citations

6
avg, IF

6.24
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 302 | Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer.. <i>Diagnostics</i> , 2022 , 12, | 3.8 | 3 |
| 301 | The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periapillary Diseases, a Novel Approach.. <i>Cancers</i> , 2022 , 14, | 6.6 | 2 |
| 300 | The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells.. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2022 , 1-11 | 1.4 | 0 |
| 299 | Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.. <i>Communications Biology</i> , 2022 , 5, 41 | 6.7 | 2 |
| 298 | A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma.. <i>Cancers</i> , 2022 , 14, | 6.6 | 1 |
| 297 | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4.. <i>Molecules</i> , 2022 , 27, | 4.8 | 4 |
| 296 | The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells.. <i>Drug Resistance Updates</i> , 2022 , 62, 100833 | 23.2 | 1 |
| 295 | Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.. <i>Toxicology and Applied Pharmacology</i> , 2022 , 440, 115951 | 4.6 | 0 |
| 294 | "Depart from evil, and do good": turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103659 | 7 | |
| 293 | Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. <i>Biomolecules</i> , 2022 , 12, 651 | 5.9 | 1 |
| 292 | Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma.. <i>Expert Review of Clinical Pharmacology</i> , 2022 , 1-18 | 3.8 | 0 |
| 291 | A New Generation of Vaccines in the Age of Immunotherapy. <i>Current Oncology Reports</i> , 2021 , 23, 137 | 6.3 | 3 |
| 290 | SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. 2021 , 4, 904-922 | | |
| 289 | Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. <i>Oncologist</i> , 2021 , 26, e2306-e2307 | 5.7 | 1 |
| 288 | Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2021 , | 12.7 | 10 |
| 287 | Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 91 | 12.8 | 9 |
| 286 | A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3135-3137 | 4.9 | |

| | | | |
|-----|--|------|----|
| 285 | Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103234 | 7 | 11 |
| 284 | Organotypic-liver slice culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 937-946 | 5.5 | 1 |
| 283 | Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. <i>Epigenetics</i> , 2021 , 1-24 | 5.7 | 1 |
| 282 | Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 867-868 | 5.5 | 1 |
| 281 | Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021 , 209, 112857 | 6.8 | 9 |
| 280 | Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm-Associated Infections. <i>ChemMedChem</i> , 2021 , 16, 65-80 | 3.7 | 37 |
| 279 | 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3 β Kinase. <i>ChemMedChem</i> , 2021 , 16, 537-554 | 3.7 | 12 |
| 278 | The role of the microbiome in drug resistance in gastrointestinal cancers. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 165-176 | 3.5 | 6 |
| 277 | Tumor grafted - chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 947-968 | 5.5 | 9 |
| 276 | Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. <i>Nature Communications</i> , 2021 , 12, 1270 | 17.4 | 25 |
| 275 | The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response-Letter. <i>Clinical Cancer Research</i> , 2021 , 27, 4126 | 12.9 | 0 |
| 274 | Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. <i>Gastroenterology</i> , 2021 , 161, 1758-1763 | 13.3 | 2 |
| 273 | Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). <i>Cancers</i> , 2021 , 13, | 6.6 | 9 |
| 272 | Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway. <i>Cellular Signalling</i> , 2021 , 85, 110069 | 4.9 | 2 |
| 271 | Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. <i>European Journal of Cancer</i> , 2021 , 157, 520-522 | 7.5 | |
| 270 | GSK3 β as a novel promising target to overcome chemoresistance in pancreatic cancer. <i>Drug Resistance Updates</i> , 2021 , 58, 100779 | 23.2 | 12 |
| 269 | Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 166, 103454 | 7 | 5 |
| 268 | 1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A. <i>European Journal of Medicinal Chemistry</i> , 2021 , 209, 112892 | 6.8 | 23 |

| | | | |
|-----|---|------|----|
| 267 | A New Oxadiazole-Based Toposentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.. <i>Molecules</i> , 2021 , 27, | 4.8 | 9 |
| 266 | The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. <i>Cancers</i> , 2020 , 12, | 6.6 | 13 |
| 265 | Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. <i>British Journal of Cancer</i> , 2020 , 123, 644-656 | 8.7 | 15 |
| 264 | Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020 , 12, | 6.6 | 9 |
| 263 | Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF- κ B signaling pathways. <i>Life Sciences</i> , 2020 , 249, 117470 | 6.8 | 17 |
| 262 | Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation. <i>Cancers</i> , 2020 , 12, | 6.6 | 6 |
| 261 | Thiazoles, Their Benzofused Systems, and Thiazolidinone Derivatives: Versatile and Promising Tools to Combat Antibiotic Resistance. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 7923-7956 | 8.3 | 50 |
| 260 | Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , 2020 , 25, e634-e643 | 5.7 | 18 |
| 259 | 3-(6-Phenylimidazo [2,1-][1,3,4]thiadiazol-2-yl)-1-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Molecules</i> , 2020 , 25, | 4.8 | 22 |
| 258 | Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020 , 189, 112088 | 6.8 | 32 |
| 257 | Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. <i>Journal of Cellular Physiology</i> , 2020 , 235, 8085-8097 | 7 | 5 |
| 256 | The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 567-582 | 5.9 | 18 |
| 255 | Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. <i>JCI Insight</i> , 2020 , 5, | 9.9 | 17 |
| 254 | Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. <i>Oncoscience</i> , 2020 , 7, 76-80 | 0.8 | 1 |
| 253 | Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. <i>Oncoscience</i> , 2020 , 7, 76-80 | 0.8 | 2 |
| 252 | Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas. <i>Cancers</i> , 2020 , 13, | 6.6 | 7 |
| 251 | Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. <i>Gut</i> , 2020 , 69, 404-405 | 19.2 | 3 |
| 250 | The role of alternative splicing in cancer: From oncogenesis to drug resistance. <i>Drug Resistance Updates</i> , 2020 , 53, 100728 | 23.2 | 33 |

| | | | |
|-----|---|------|-----|
| 249 | "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. <i>Cancers</i> , 2020 , 12, | 6.6 | 7 |
| 248 | Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. <i>Cancers</i> , 2020 , 12, | 6.6 | 3 |
| 247 | Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 18 | 7.8 | 7 |
| 246 | Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , 2020 , 123, 1464-1465 | 8.7 | |
| 245 | The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer. <i>Anticancer Research</i> , 2020 , 40, 4807-4818 | 2.3 | 13 |
| 244 | New Imidazo[2,1-][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. <i>Anticancer Research</i> , 2020 , 40, 4913-4919 | 2.3 | 4 |
| 243 | Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 1147-1159 | 7.2 | 10 |
| 242 | Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 , 271, 1137-1147 | 7.8 | 23 |
| 241 | The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2020 , 60, 238-248 | 12.7 | 26 |
| 240 | Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1287-1298 | 4 | 9 |
| 239 | Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019 , 11, | 6.6 | 11 |
| 238 | PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , 2019 , 11, | 6.6 | 35 |
| 237 | HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019 , 56, 533-566 | 9.4 | 53 |
| 236 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019 , 121, 725-737 | 8.7 | 295 |
| 235 | Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019 , 46, 100644 | 23.2 | 67 |
| 234 | Breastfeeding during R-CHOP chemotherapy: please abstain!. <i>European Journal of Cancer</i> , 2019 , 119, 107-111 | 7.5 | 2 |
| 233 | Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 140, 8-16 | 7 | 13 |
| 232 | Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919841233 | 5.4 | 21 |

| | | | |
|-----|--|-----|----|
| 231 | Pharmacogenetics of treatments for pancreatic cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 437-447 | 5.5 | 15 |
| 230 | Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 461-471 | 3.5 | 7 |
| 229 | Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. <i>Cancers</i> , 2019 , 11, | 6.6 | 33 |
| 228 | Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019 , 166, 128-138 | 6 | 9 |
| 227 | Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1213-1214 | 3.8 | 3 |
| 226 | RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 311-322 | 5.9 | 12 |
| 225 | Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. <i>Cellular Oncology (Dordrecht)</i> , 2019 , 42, 261-273 | 7.2 | 29 |
| 224 | Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies 2019 , 25-60 | | 0 |
| 223 | Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-][1,3,4]thiadiazol-2-yl)-1-indole Derivatives Against Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2019 , 39, 3615-3620 | 2.3 | 16 |
| 222 | To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. <i>Anticancer Research</i> , 2019 , 39, 3303-3309 | 2.3 | 6 |
| 221 | Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. <i>Anticancer Research</i> , 2019 , 39, 3609-3614 | 2.3 | 4 |
| 220 | Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). <i>Annals of Oncology</i> , 2019 , 30, v931-v932 ^{10.3} | | 5 |
| 219 | Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, But do they contradict themselves?. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102824 | 7 | 3 |
| 218 | Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1033-1036 ³ | | |
| 217 | Targeting the Ribosome Biogenesis Key Molecule Fibrillarlin to Avoid Chemoresistance. <i>Current Medicinal Chemistry</i> , 2019 , 26, 6020-6032 | 4.3 | 18 |
| 216 | 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019 , 167, 200-210 | 6.8 | 29 |
| 215 | Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?. <i>JCO Precision Oncology</i> , 2019 , 3, 1-2 | 3.6 | |
| 214 | New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1081-1090 ^{3.8} | | 12 |

| | | | |
|-----|--|------|----|
| 213 | CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. <i>Molecules</i> , 2019 , 24, | 4.8 | 6 |
| 212 | The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. <i>Molecules</i> , 2019 , 24, | 4.8 | 2 |
| 211 | Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019 , 39, 215-225 | 8.8 | 27 |
| 210 | MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. <i>Drug Resistance Updates</i> , 2019 , 42, 1-11 | 23.2 | 43 |
| 209 | Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance. <i>European Journal of Medicinal Chemistry</i> , 2019 , 161, 154-178 | 6.8 | 77 |
| 208 | Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018 , 52, 259-268 | 12.7 | 9 |
| 207 | Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 39-48 | 3.5 | 3 |
| 206 | Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. <i>Clinical Lung Cancer</i> , 2018 , 19, 35-41 | 4.9 | 8 |
| 205 | TGF- β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018 , 9, 1845 | 17.4 | 61 |
| 204 | Abstract 493: Circulating biliary tract microRNA signature discriminates cholangiocarcinoma from pancreatic cancer 2018 , | | 2 |
| 203 | 5'Nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 16437-16450 | 3.3 | 6 |
| 202 | Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. <i>Oncotarget</i> , 2018 , 9, 19006-19013 | 3.3 | 71 |
| 201 | Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2018 , | 4.5 | 5 |
| 200 | Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , 2018 , 24, 4601-4604 | 3.3 | 2 |
| 199 | Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24078-e24078 | 2.2 | |
| 198 | A synthetic lethal bullet. <i>Nature Nanotechnology</i> , 2018 , 13, 6-7 | 28.7 | 7 |
| 197 | Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. <i>British Journal of Cancer</i> , 2018 , 119, 1326-1331 | 8.7 | 9 |
| 196 | The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 1005-1009 | 3.8 | 17 |

| | | | |
|-----|---|------|-----|
| 195 | Multidrug-resistant transporter expression does not always result in drug resistance. <i>Cancer Science</i> , 2018 , 109, 3360-3362 | 6.9 | 1 |
| 194 | Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 9 | 22.4 | 48 |
| 193 | miRNAs: micro-managers of anticancer combination therapies. <i>Angiogenesis</i> , 2017 , 20, 269-285 | 10.6 | 47 |
| 192 | Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. <i>Seminars in Cancer Biology</i> , 2017 , 44, 43-59 | 12.7 | 59 |
| 191 | Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. <i>Seminars in Cancer Biology</i> , 2017 , 44, 153-169 | 12.7 | 39 |
| 190 | Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 995, 97-125 | 3.6 | 69 |
| 189 | Drug resistance in pancreatic cancer: Impact of altered energy metabolism. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 114, 139-152 | 7 | 123 |
| 188 | Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. <i>Scientific Reports</i> , 2017 , 7, 44686 | 4.9 | 36 |
| 187 | Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. <i>Annals of Oncology</i> , 2017 , 28, 2725-2732 | 10.3 | 29 |
| 186 | Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. <i>OncoTargets and Therapy</i> , 2017 , 10, 4535-4541 | 4.4 | 18 |
| 185 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 692-693 | 2.2 | 1 |
| 184 | miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. <i>Pharmacogenomics</i> , 2017 , 18, 1343-1358 | 2.6 | 32 |
| 183 | Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers. <i>Current Clinical Pathology</i> , 2017 , 137-150 | 0.1 | |
| 182 | Resistance Mechanisms to AZD9291 and Rociletinib-Letter. <i>Clinical Cancer Research</i> , 2017 , 23, 3966 | 12.9 | |
| 181 | A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. <i>Drug Resistance Updates</i> , 2017 , 31, 43-51 | 23.2 | 31 |
| 180 | Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , 2017 , 32, 238-252.e9 | 24.3 | 150 |
| 179 | Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. <i>Scientific Reports</i> , 2017 , 7, 16623 | 4.9 | 33 |
| 178 | Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 2047-2063 | 4.4 | 19 |

| | | | |
|-----|---|------|------|
| 177 | New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. <i>Frontiers in Oncology</i> , 2017 , 7, 170 | 5.3 | 14 |
| 176 | Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017 , 8, 53068-53083 | 3.3 | 15 |
| 175 | Molecular mechanism underlying the pharmacological interactions of the protein kinase C- β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. <i>American Journal of Cancer Research</i> , 2017 , 7, 816-830 | 4.4 | 2 |
| 174 | Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?. <i>Translational Cancer Research</i> , 2017 , 6, S1010-S1013 | 0.3 | 2 |
| 173 | The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20043-e20043 | 2.2 | |
| 172 | Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1155-1162 | 3.8 | 6 |
| 171 | hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016 , 21, e4 | 5.7 | 3 |
| 170 | The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. <i>Clinical Cancer Research</i> , 2016 , 22, 2594 | 12.9 | |
| 169 | Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. <i>Journal of Clinical Oncology</i> , 2016 , 34, 511-2 | 2.2 | 3 |
| 168 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222 | 10.2 | 3838 |
| 167 | On the pharmacogenetics of non-small cell lung cancer treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 307-17 | 5.5 | 20 |
| 166 | The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 385-92 | 5.9 | 18 |
| 165 | Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , 2016 , 10, 417-30 | 2.3 | 13 |
| 164 | The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. <i>Methods in Molecular Biology</i> , 2016 , 1395, 163-87 | 1.4 | 9 |
| 163 | Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 147-57 | 3.5 | 27 |
| 162 | Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. <i>Oncotarget</i> , 2016 , 7, 5240-57 | 3.3 | 16 |
| 161 | Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , 2016 , 7, 28556-69 | 3.3 | 16 |
| 160 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6987-7005 | 5.6 | 52 |

| | | | |
|-----|--|------|-----|
| 159 | Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. <i>Journal of Visualized Experiments</i> , 2016 , | 1.6 | 14 |
| 158 | Role of Akt signaling in resistance to DNA-targeted therapy. <i>World Journal of Clinical Oncology</i> , 2016 , 7, 352-369 | 2.5 | 35 |
| 157 | Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2016 , 7, 425-432 | 2.5 | 4 |
| 156 | New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?. <i>OncoTargets and Therapy</i> , 2016 , 9, 6065-6074 | 4.4 | 28 |
| 155 | A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016 , 35, 643-651 | 1.4 | 6 |
| 154 | cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1423-328.9 | | 38 |
| 153 | Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 733-6 | 3.8 | 7 |
| 152 | Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 781-98 | 3.8 | 23 |
| 151 | Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1-12 | 3.5 | 99 |
| 150 | MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer. <i>Current Pharmacology Reports</i> , 2015 , 1, 223-233 | 5.5 | 3 |
| 149 | microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1389-404 | 7.5 | 80 |
| 148 | Platinum-induced neurotoxicity and preventive strategies: past, present, and future. <i>Oncologist</i> , 2015 , 20, 411-32 | 5.7 | 151 |
| 147 | Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 768-9 | 0.7 | 2 |
| 146 | Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S37 | 4.0 | 41 |
| 145 | Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4569-75 | 12.9 | 10 |
| 144 | Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. <i>Seminars in Cancer Biology</i> , 2015 , 35, 11-9 | 12.7 | 29 |
| 143 | Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1493-500 | 5.9 | 81 |
| 142 | Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1525-9 | 3.8 | 21 |

| | | | |
|-----|---|------|-----|
| 141 | MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. <i>Clinical Epigenetics</i> , 2015 , 7, 129 | 7.7 | 16 |
| 140 | Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 1189-94 | 4.9 | 16 |
| 139 | NF- κ B drives acquired resistance to a novel mutant-selective EGFR inhibitor. <i>Oncotarget</i> , 2015 , 6, 42717-33 | 3.3 | 27 |
| 138 | MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 37269-80 | 3.3 | 112 |
| 137 | c-Met as a Target for Personalized Therapy. <i>Translational Oncogenomics</i> , 2015 , 7, 13-31 | | 90 |
| 136 | Pharmacology and Clinical Development of New Molecularly Targeted Agents. <i>Current Clinical Pathology</i> , 2015 , 9-29 | 0.1 | |
| 135 | Abstract 4335: Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed 2015 , | | 2 |
| 134 | Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 300-13 | 7 | 56 |
| 133 | Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt346 | 9.7 | 39 |
| 132 | Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. <i>British Journal of Cancer</i> , 2014 , 110, 172-82 | 8.7 | 99 |
| 131 | miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014 , 33, 384-93 | 1.4 | 45 |
| 130 | On the use of pharmacogenetics in cancer treatment and clinical trials. <i>European Journal of Cancer</i> , 2014 , 50, 2532-43 | 7.5 | 19 |
| 129 | SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter. <i>Clinical Cancer Research</i> , 2014 , 20, 3623-4 | 4.9 | 4 |
| 128 | Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 446-56 | 11.2 | 13 |
| 127 | Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 990-1004 | 14.4 | 60 |
| 126 | AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. <i>PLoS ONE</i> , 2014 , 9, e108057 | 3.7 | 19 |
| 125 | Tivantinib-Gemcitabine: Pharmacological Rational for a New Combination in Pancreatic Cancer. <i>Annals of Oncology</i> , 2014 , 25, iv158 | 10.3 | 3 |
| 124 | Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014 , 33, 403-12 | 1.4 | 14 |

| | | | |
|-----|--|------|-----|
| 123 | A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , 2014 , 15, 609-18 | 2.6 | 9 |
| 122 | A microRNA meta-signature for pancreatic ductal adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 267-71 | 3.8 | 27 |
| 121 | Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. <i>BioMed Research International</i> , 2014 , 2014, 678401 | 3 | 35 |
| 120 | CYB5A and autophagy-mediated cell death in pancreatic cancer. <i>Autophagy</i> , 2014 , 10, 697-8 | 10.2 | 5 |
| 119 | Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3341 | 2.2 | 3 |
| 118 | MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. <i>Gastroenterology</i> , 2014 , 146, 268-77.e18 | 13.3 | 125 |
| 117 | Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML. <i>Blood</i> , 2014 , 124, 924-924 | 2.2 | 2 |
| 116 | Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/βcatenin signalling in pancreatic adenocarcinoma. <i>Oncotarget</i> , 2014 , 5, 5335-49 | 3.3 | 40 |
| 115 | MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside. <i>Current Medicinal Chemistry</i> , 2014 , 21, 975-89 | 4.3 | 14 |
| 114 | Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3863-74 | 3.3 | 3 |
| 113 | Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 475-85 | 2.6 | 47 |
| 112 | The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib. <i>Current Drug Targets</i> , 2014 , 15, 1322-30 | 3 | 19 |
| 111 | Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. <i>Current Drug Targets</i> , 2014 , 15, 1331-40 | 3 | 16 |
| 110 | Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. <i>Anticancer Research</i> , 2014 , 34, 435-42 | 2.3 | 20 |
| 109 | Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. <i>Anticancer Research</i> , 2014 , 34, 517-23 | 2.3 | 16 |
| 108 | An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. <i>Cancer</i> , 2013 , 119, 2662-3 | 6.4 | 1 |
| 107 | Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. <i>International Journal of Cancer</i> , 2013 , 133, 1016-22 | 7.5 | 20 |
| 106 | Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 207-11 | 14.4 | 42 |

| | | | |
|-----|--|------|----|
| 105 | USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. <i>Molecular Cancer</i> , 2013 , 12, 91 | 42.1 | 76 |
| 104 | MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013 , 18, 851-60 | 5.4 | 32 |
| 103 | Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. <i>Expert Review of Molecular Diagnostics</i> , 2013 , 13, 325-9 | 3.8 | 9 |
| 102 | The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. <i>Annals of Oncology</i> , 2013 , 24, 734-41 | 10.3 | 72 |
| 101 | Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. <i>Neoplasia</i> , 2013 , 15, 61-72 | 6.4 | 12 |
| 100 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 818-832 | 3.3 | 23 |
| 99 | Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI. <i>Pteridines</i> , 2013 , 24, 69-79 | 0.6 | 2 |
| 98 | Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 940-950 | 3.3 | 46 |
| 97 | Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. <i>Current Pharmaceutical Design</i> , 2013 , 19, 927-939 | 3.3 | 27 |
| 96 | A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. <i>Oncology Letters</i> , 2013 , 6, 1487-1491 | 2.6 | 10 |
| 95 | Serum miR-1290 as a marker of pancreatic cancer--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 5250-1 | 12.9 | 3 |
| 94 | Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. <i>Cancer Research</i> , 2013 , 73, 6745-56 | 10.1 | 65 |
| 93 | Gender, cytidine deaminase, and 5-aza/decitabine--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 3105 | 12.9 | 8 |
| 92 | "One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e79-80 | 8.9 | 2 |
| 91 | Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer). <i>Current Pharmaceutical Design</i> , 2013 , 19, 807-807 | 3.3 | |
| 90 | Thymidylate synthase inhibitors for thoracic tumors. <i>Pteridines</i> , 2013 , 24, 57-67 | 0.6 | 0 |
| 89 | Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3-Deoxy-3-[¹⁸ F]fluorothymidine positron emission tomography. <i>PLoS ONE</i> , 2013 , 8, e63705 | 3.7 | 17 |
| 88 | Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. <i>PLoS ONE</i> , 2013 , 8, e78656 | 3.7 | 31 |

| | | | |
|----|---|------|-----|
| 87 | Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncogenesis</i> , 2013 , 18, 317-26 | 1.3 | 9 |
| 86 | Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 818-32 | 3.3 | 12 |
| 85 | Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. <i>Current Pharmaceutical Design</i> , 2013 , 19, 927-39 | 3.3 | 12 |
| 84 | Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. <i>Current Pharmaceutical Design</i> , 2013 , 19, 940-50 | 3.3 | 20 |
| 83 | Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 103-22 | 7 | 117 |
| 82 | Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1275-8 | 3.5 | 3 |
| 81 | EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. <i>Future Oncology</i> , 2012 , 8, 1015-29 | 3.6 | 15 |
| 80 | Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 524-33 | 12.9 | 19 |
| 79 | Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. <i>Pharmacogenomics</i> , 2012 , 13, 1073-86 | 2.6 | 26 |
| 78 | Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity. <i>Pharmacogenomics</i> , 2012 , 13, 1445-7 | 2.6 | 1 |
| 77 | Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. <i>Lung Cancer</i> , 2012 , 78, 92-9 | 5.9 | 32 |
| 76 | High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. <i>PLoS ONE</i> , 2012 , 7, e49145 | 3.7 | 57 |
| 75 | "The only thing I know is that I know nothing": 5-fluorouracil in human milk. <i>Annals of Oncology</i> , 2012 , 23, 543-4 | 10.3 | 7 |
| 74 | Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 670-677 | 10.3 | 38 |
| 73 | Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. <i>Current Pharmaceutical Design</i> , 2012 , 18, 2811-29 | 3.3 | 39 |
| 72 | TFAP2E-DKK4 and chemoresistance in colorectal cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 966; author reply 966 | 59.2 | 9 |
| 71 | Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1735-46 | 6.1 | 73 |
| 70 | Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1649-59 | 3 | 21 |

| | | | |
|----|---|------|-----|
| 69 | Evaluation of EZH2 SNPs in cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10611-10611 | | |
| 68 | Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. <i>Pancreatology</i> , 2011 , 11, 30-42 | 3.8 | 11 |
| 67 | Thymidylate synthase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1343-56 | 5.9 | 24 |
| 66 | Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. <i>Clinical Cancer Research</i> , 2011 , 17, 2581-90 | 12.9 | 78 |
| 65 | Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 1599-612 | 8.3 | 152 |
| 64 | Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 695-701 | 3.8 | 20 |
| 63 | Analysis of drug interactions. <i>Methods in Molecular Biology</i> , 2011 , 731, 421-34 | 1.4 | 141 |
| 62 | Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. <i>Frontiers in Bioscience - Landmark</i> , 2011 , 16, 116-30 | 2.8 | 7 |
| 61 | Tyrosine kinase inhibitors: Multi-targeted or single-targeted?. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 80-93 | 2.5 | 131 |
| 60 | DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. <i>Current Drug Metabolism</i> , 2011 , 12, 956-65 | 3.5 | 7 |
| 59 | Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 768-73 | 8.9 | 5 |
| 58 | Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 395-6 | 8.9 | 35 |
| 57 | N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 5398-407 | 6.8 | 54 |
| 56 | Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011 , 30, 1203-13 | 1.4 | 6 |
| 55 | Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , 2011 , 12, 1641-52 | 2.6 | 36 |
| 54 | Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. <i>Annals of Oncology</i> , 2011 , 22, 482-4 | 10.3 | 8 |
| 53 | Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011 , 12, 159-70 | 2.6 | 58 |
| 52 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. <i>British Journal of Cancer</i> , 2011 , 105, 1542-53 | 8.7 | 32 |

| | | | |
|----|--|------|-----|
| 51 | Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011 , 30, 1214-22 | 1.4 | 28 |
| 50 | Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). <i>Current Drug Targets</i> , 2010 , 11, 12-28 | 3 | 13 |
| 49 | A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 3078-87 | 12.9 | 77 |
| 48 | New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. <i>Annals of Oncology</i> , 2010 , 21, 1560-1561 | 10.3 | 10 |
| 47 | Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. <i>Journal of Clinical Oncology</i> , 2010 , 28, e221-2; author reply e223-5 | 2.2 | 21 |
| 46 | Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010 , 29, 419-26 | 1.4 | 11 |
| 45 | Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2010 , 29, 408-13 | 1.4 | 7 |
| 44 | Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010 , 10, 180-90 | 3.5 | 16 |
| 43 | MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. <i>Cancer Research</i> , 2010 , 70, 4528-38 | 10.1 | 361 |
| 42 | Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 581-93 | 6.1 | 59 |
| 41 | Differences of gene expression in non-small cell lung cancer: are histology, tumor site, and methodology relevant?. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1310-1; author reply 1311 | 8.9 | 1 |
| 40 | Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 547-58 | 3.5 | 17 |
| 39 | Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 1059-68 | 3.2 | 73 |
| 38 | Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010 , 10, 511 | 4.8 | 38 |
| 37 | Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. <i>PLoS ONE</i> , 2010 , 5, e10630 | 3.7 | 230 |
| 36 | Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. <i>British Journal of Cancer</i> , 2009 , 100, 1120-7 | 8.7 | 29 |
| 35 | Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. <i>Pharmacogenomics</i> , 2009 , 10, 69-80 | 2.6 | 35 |
| 34 | Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 655-64 | 6.1 | 23 |

| | | | |
|----|---|------|-----|
| 33 | Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1964-73 | 6.1 | 38 |
| 32 | Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1026-36 | 6.1 | 14 |
| 31 | Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 21-44 | 7 | 17 |
| 30 | Pharmacogenomics in non-small-cell lung cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 408-17 | 18.5 | 24 |
| 29 | Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 146-54 | 3.8 | 13 |
| 28 | Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. <i>Laboratory Investigation</i> , 2008 , 88, 773-84 | 5.9 | 29 |
| 27 | Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. <i>British Journal of Cancer</i> , 2008 , 99, 750-9 | 8.7 | 40 |
| 26 | Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. <i>Molecular Pharmacology</i> , 2008 , 73, 1290-300 | 4.3 | 130 |
| 25 | Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008 , 27, 740-5 | 1.4 | 4 |
| 24 | Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008 , 27, 720-5 | 1.4 | 50 |
| 23 | Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008 , 27, 787-93 | 1.4 | 7 |
| 22 | Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 1797-803 | 12.9 | 170 |
| 21 | Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2008 , 19, 1605-12 | 10.3 | 74 |
| 20 | Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. <i>International Journal of Cancer</i> , 2008 , 123, 1712-20 | 7.5 | 26 |
| 19 | Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. <i>Leukemia Research</i> , 2008 , 32, 19-24 | 2.7 | 38 |
| 18 | Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. <i>Pharmacological Research</i> , 2007 , 55, 343-9 | 10.2 | 24 |
| 17 | Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. <i>British Journal of Cancer</i> , 2007 , 96, 769-75 | 8.7 | 50 |
| 16 | The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S27-30 | 8.9 | 4 |

| | | | |
|----|---|------|-----|
| 15 | Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration. <i>Journal of Clinical Oncology</i> , 2007 , 25, 14145-14145 | 2.2 | |
| 14 | Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. <i>Cancer Research</i> , 2006 , 66, 3928-35 | 10.1 | 276 |
| 13 | In vitro studies on gemcitabine combinations with other antineoplastics. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v17-19 | 10.3 | 7 |
| 12 | Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1387-95 | 6.1 | 72 |
| 11 | Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7099-107 | 12.9 | 47 |
| 10 | In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006 , 95, 289-97 | 8.7 | 37 |
| 9 | Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. <i>Molecular Pharmacology</i> , 2005 , 68, 110-8 | 4.3 | 163 |
| 8 | Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. <i>British Journal of Cancer</i> , 2005 , 92, 681-9 | 8.7 | 24 |
| 7 | Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2005 , 93, 35-40 | 8.7 | 55 |
| 6 | Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. <i>Clinical Cancer Research</i> , 2004 , 10, 2936-43 | 12.9 | 81 |
| 5 | Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. <i>Il Farmaco</i> , 2003 , 58, 85-9 | | 2 |
| 4 | Ceramide analogues in apoptosis: a new strategy for anticancer drug development. <i>Il Farmaco</i> , 2003 , 58, 205-11 | | 12 |
| 3 | Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 3994-4000 | 8.3 | 47 |
| 2 | Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001 , 12, 1553-9 | 10.3 | 29 |
| 1 | A mechanical memory of pancreatic cancer cells | | 1 |